Efficacy of Poststroke Intensive Rosuvastatin Treatment for Aortogenic Embolic Stroke (EPISTEME trial)

INTERVENTION: Treatment with rosuvastatin 5mg daily Treatment without rosuvastatin CONDITION: Brain infarction or transient ischemic attack with atheromatous plaques in the aortic arch PRIMARY OUTCOME: Morphological alteration of atheromatous plaques in the aortic arch SECONDARY OUTCOME: 1) Alteration of atheromatous plaques in the aortic arch ; 2) Changes in lipid profile; 3) Changes in inflammatory markers and white blood cell count; 4) Recurrence of ischemic stroke; 5) Prevalence of hemorrhagic stroke including intracranial brain hemorrhage and subarachnoid hemorrhage; 6) Prevalence of coronary artery disease; 7) Other vascular diseases; 8) Death INCLUSION CRITERIA: 1) Patients with brain infarction or transient ischemic attack within 7 days after onset, having atheromatous aortic plaques greater than 4mm in size 2) Patients with hypercholesterolemia (Serum LDL‐C levels greater than 140mg/dL)